Bahram Valamehr Ph.D.
Net Worth

Last updated:

What is Bahram Valamehr Ph.D. net worth?

The estimated net worth of Dr. Bahram Valamehr Ph.D. is at least $17,067,803 as of 9 Jan 2024. He owns shares worth $180,167 as insider, has earned $13,377,636 from insider trading and has received compensation worth at least $3,510,000 in Fate Therapeutics, Inc..

What is the salary of Bahram Valamehr Ph.D.?

Dr. Bahram Valamehr Ph.D. salary is $585,000 per year as Chief R&D Officer in Fate Therapeutics, Inc..

How old is Bahram Valamehr Ph.D.?

Dr. Bahram Valamehr Ph.D. is 48 years old, born in 1977.

What stocks does Bahram Valamehr Ph.D. currently own?

As insider, Dr. Bahram Valamehr Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Fate Therapeutics, Inc. (FATE) Chief R&D Officer 158,069 $1.14 $180,167

What does Fate Therapeutics, Inc. do?

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE logo
FATE
Fate Therapeutics, Inc.
$1.14

Bahram Valamehr Ph.D. insider trading

Fate Therapeutics, Inc.

Dr. Bahram Valamehr Ph.D. has made 25 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 11,271 units of FATE stock worth $49,367 on 9 Jan 2024.

The largest trade he's ever made was exercising 25,000 units of FATE stock on 14 Sep 2020. As of 9 Jan 2024 he still owns at least 158,069 units of FATE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 11,271 $4.38 $49,367
Option
Common Stock 423 $1.37 $580
Option
Stock Option (Right to Buy) 423 $1.37 $580
Sale
Common Stock 10,917 $5.24 $57,205
Option
Stock Option (Right to Buy) 17,158 $2.73 $46,841
Sale
Common Stock 17,158 $30.23 $518,686
Option
Common Stock 17,158 $2.73 $46,841
Sale
Common Stock 7,842 $30.07 $235,809
Option
Common Stock 5,842 $2.73 $15,949
Option
Stock Option (Right to Buy) 2,000 $4.84 $9,680
Option
Stock Option (Right to Buy) 5,842 $2.73 $15,949
Option
Common Stock 2,000 $4.84 $9,680
Option
Stock Option (Right to Buy) 25,000 $2.73 $68,250
Option
Common Stock 25,000 $2.73 $68,250
Sale
Common Stock 100 $34.04 $3,404
Sale
Common Stock 2,960 $33.3 $98,568
Sale
Common Stock 2,195 $32.49 $71,316
Sale
Common Stock 3,067 $31.66 $97,101
Sale
Common Stock 16,678 $30.36 $506,344
Sale
Common Stock 4,570 $48.78 $222,925
Sale
Common Stock 5,596 $46.75 $261,613
Sale
Common Stock 25,000 $47.61 $1,190,150
Option
Stock Option (Right to Buy) 25,000 $2.73 $68,250
Option
Common Stock 25,000 $2.73 $68,250
Sale
Common Stock 25,000 $2.73 $68,250
Sale
Stock Option (Right to Buy) 15,809 $2.73 $43,159
Sale
Common Stock 9,191 $67.15 $617,166
Option
Common Stock 25,000 $66.75 $1,668,650
Option
Stock Option (Right to Buy) 25,000 $2.73 $68,250
Option
Stock Option (Right to Buy) 25,000 $2.73 $68,250
Sale
Common Stock 25,000 N/A N/A
Option
Common Stock 25,000 N/A N/A
Option
Stock Option (Right to Buy) 25,000 N/A N/A
Option
Common Stock 25,000 $2.9 $72,500
Option
Stock Option (Right to Buy) 25,000 $2.9 $72,500
Sale
Common Stock 25,000 $92.76 $2,319,100
Sale
Common Stock 25,000 $92.76 $2,319,100
Sale
Common stock 3,254 $110.68 $360,140
Sale
Common stock 6,230 $116.33 $724,717
Sale
Common stock 23,187 N/A N/A
Option
Stock Option (right to buy) 25,000 N/A N/A
Option
Common stock 25,000 $2.9 $72,500
Sale
Common stock 25,000 $99.32 $2,483,100
Sale
Common stock 25,000 $36.98 $924,575
Option
Stock Option (right to buy) 25,000 $2.3 $57,375
Option
Common stock 25,000 $2.3 $57,375
Option
Common Stock 1,153 $1.69 $1,949
Option
Stock Option (right to buy) 1,153 $1.69 $1,949
Sale
Common Stock 5,700 $20.69 $117,950
Sale
Common Stock 6,200 $14.18 $87,891

Fate Therapeutics key executives

Fate Therapeutics, Inc. executives and other stock owners filed with the SEC: